Looking for a new broker?
Biophytis SA stock is down -3.85% since 30 days ago. The next earnings date is Jan 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.
Biophytis S.A. focuses on the development of therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases.
